Receipt of HPV Vaccine Associated with Increased Prevalence of High-Risk HPV Infections
DOI:
https://doi.org/10.56098/ijvtpr.v2i1.28Keywords:
aluminum adjuvant, HPV vaccine, type-replacement, vaccine safetyAbstract
Identifying possible negative side effects of vaccines helps to determine whether benefits outweigh the costs of a medical intervention that claims to prevent a disease. Such a cost-benefit analysis is essential both for vaccine policy as well as informed consent. This study seeks to determine whether the use of the human papillomavirus (HPV) vaccine is related to an increase in high-risk (HR), possibly cancer related, HPV infections. Data from the U.S. National Health and Examination Nutrition Survey reveal a statistically significantly higher percentage of women who received an HPV vaccine carried an HR-HPV than women who did not receive an HPV shot (Rao-Scott Chi-square contrast p-value of 0.002). Vaccine recipients tested positive less frequently for HPVs targeted by the vaccines, but had a higher prevalence of other HR (cancer related) HPVs. The results suggest that a thorough investigation of the effects of HPV vaccines on HR-HPV viruses (and other pathogens) not targeted by them is warranted.
References
Benn, C. S., Netea, M. G., Selin, L. K., & Aaby, P. (2013). A small jab—A big effect: Nonspecific immunomodulation by vaccines. Trends Immunol, 34(9), 431–439. https://doi.org/S1471-4906(13)00058-6 [pii] 10.1016/j.it.2013.04.004
Canadian Agency for Drugs and Technologies in Health. (2013). Genotyping of Human Papillomavirus Viruses Using Linear Array. https://www.cadth.ca/sites/default/files/pdf/lab-tests/04_Genotyping_of_HPV_e.pdf
Centers for Disease Control and Prevention. (2019). National Health and Nutrition Examination Survey. https://www.cdc.gov/nchs/nhanes/index.htm
Chen, T.-C., Clark, J., Riddles, M., & Mohadjer, L. K. (2020). National Health and Nutrition Examination Survey, 2015-2018: Sample Design and Estimation Procedures. Vital and Health Statistics, 2(184). https://www.cdc.gov/nchs/data/series/sr_02/sr02-184-508.pdf
Eklund, C., Forslund, O., Wallin, K.-L., & Dillner, J. (2014). Global improvement in genotyping of human papillomavirus DNA: The 2011 HPV LabNet International Proficiency Study. Journal of Clinical Microbiology, 52(2), 449–459. https://doi.org/10.1128/JCM.02453-13
Eklund, C., Forslund, O., Wallin, K.-L., Zhou, T., & Dillner, J. (2012). The 2010 Global Proficiency Study of Human Papillomavirus Genotyping in Vaccinology. Journal of Clinical Microbiology. https://journals.asm.org/doi/abs/10.1128/jcm.00840-12
Flores-Miramontes, M. G., Torres-Reyes, L. A., Alvarado-Ruíz, L., Romero-Martínez, S. A., Ramírez-Rodríguez, V., Balderas-Peña, L. M. A., Vallejo-Ruíz, V., Piña-Sánchez, P., Cortés-Gutiérrez, E. I., Jave-Suárez, L. F., & Aguilar-Lemarroy, A. (2015). Human papillomavirus genotyping by Linear Array and Next-Generation Sequencing in cervical samples from Western Mexico. Virology Journal, 12(1), 161. https://doi.org/10.1186/s12985-015-0391-4
Gravitt, P. E. (2011). The known unknowns of HPV natural history. The Journal of Clinical Investigation, 121(12), 4593–4599. https://doi.org/10.1172/JCI57149
Guo, F., Hirth, J. M., & Berenson, A. B. (2015). Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years). Hum Vaccin Immunother, 11(10), 2337–2344. https://doi.org/10.1080/21645515.2015.1066948
Halec, G., Alemany, L., Lloveras, B., Schmitt, M., Alejo, M., Bosch, F. X., Tous, S., Klaustermeier, J. E., Guimera, N., Grabe, N., Lahrmann, B., Gissmann, L., Quint, W., de Sanjose, S., & Pawlita, M. (2014). Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol, 234(4), 441–451. https://doi.org/10.1002/path.4405
Holland, M., Rosenberg, K. M., & Iorio, E. (2018). The HPV Vaccine On Trial: Weighing the Evidence (Chapter 7). Skyhorse Publishing.
HPV Centre. (2015). HPV prevention at a glance. https://hpvcentre.net/hpvatglance.php
Li, M., Yang, X., Zhuang, C., Cao, Z., Ren, L., Xiu, C., Li, Y., & Zhu, Y. (2015). NE Strengthens the Immunosuppression Induced by AlCl3 Through β2-AR/cAMP Pathway in Cultured Rat Peritoneal Macrophages. Biological Trace Element Research, 164(2), 234–241. https://doi.org/10.1007/s12011-014-0217-z
Marrack, P., McKee, A. S., & Munks, M. W. (2009). Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol, 9(4), 287–293. https://doi.org/nri2510 [pii] 10.1038/nri2510
McKee, A. S., Munks, M. W., & Marrack, P. (2007). How do adjuvants work? Important considerations for new generation adjuvants. Immunity, 27(5), 687–690. https://www-sciencedirect-com.ezproxyprod.ucs.louisiana.edu/science/article/pii/S1074761307004980
Muñoz, N., Bosch, F. X., Castellsagué, X., Díaz, M., Sanjose, S. de, Hammouda, D., Shah, K. V., & Meijer, C. J. L. M. (2004). Against which human papillomavirus types shall we vaccinate and screen? The international perspective. International Journal of Cancer, 111(2), 278–285. https://doi.org/10.1002/ijc.20244
Oleszycka, E., McCluskey, S., Sharp, F. A., Muñoz-Wolf, N., Hams, E., Gorman, A. L., Fallon, P. G., & Lavelle, E. C. (2018). The vaccine adjuvant alum promotes IL-10 production that suppresses Th1 responses. European Journal of Immunology, 48(4), 705–715. https://doi.org/10.1002/eji.201747150
Rees, C. P., Brhlikova, P., & Pollock, A. M. (2020). Will HPV vaccination prevent cervical cancer? Journal of the Royal Society of Medicine, 113(2), 64–78. https://doi.org/10.1177/0141076819899308
Romagnani, S. (1996). Th1 and Th2 in human diseases. Clin Immunol Immunopathol, 80(3 Pt 1), 225–235. https://doi.org/S009012299690118X [pii] https://doi.org/10.1006/clin.1996.0118
Shardlow, E., Mold, M., & Exley, C. (2018). Unraveling the enigma: Elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action. Allergy Asthma Clin Immunol, 14, 80. https://aacijournal.biomedcentral.com/articles/10.1186/s13223-018-0305-2
Sharma, S., & Thomas, P. G. (2014). The two faces of heterologous immunity: Protection or immunopathology. J Leukoc Biol, 95(3), 405–416. https://doi.org/jlb.0713386 [pii] 10.1189/jlb.0713386
Strickler, H. D., Burk, R. D., Fazzari, M., Anastos, K., Minkoff, H., Massad, L. S., Hall, C., Bacon, M., Levine, A. M., Watts, D. H., Silverberg, M. J., Xue, X., Schlecht, N. F., Melnick, S., & Palefsky, J. M. (2005). Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst, 97(8), 577–586. https://doi.org/97/8/577 [pii] 10.1093/jnci/dji073
Theiler, R. N., Farr, S. L., Karon, J. M., Paramsothy, P., Viscidi, R., Duerr, A., Cu-Uvin, S., Sobel, J., Shah, K., Klein, R. S., & Jamieson, D. J. (2010). High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: Risk factors for cervical viral shedding. Obstet Gynecol, 115(6), 1150–1158. https://journals.lww.com/greenjournal/FullText/2010/06000/High_Risk_Human_Papillomavirus_Reactivation_in.9.aspx
VRBPAC. (2006). Background Document: GardasilTM HPV Quadrivalent Vaccine (Tables 17, 19 and 21). https://wayback.archive-it.org/7993/20180126170205/https://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf
World Health Organization. (2021). Human papillomavirus (HPV) and cervical cancer. Retrieved March 17, 2020, from https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
Downloads
Published
Versions
- 2021-09-17 (5)
- 2021-09-17 (4)
- 2021-09-17 (3)
- 2021-09-17 (2)
- 2021-09-17 (1)
Issue
Section
License
Copyright (c) 2021 Gayle Delong
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The copyright for materials in this journal, IJVTPR, is owned by the author. The author, however, grants first right of publication to the journal, IJVTPR and assures the editorial staff of the journal that the work submitted has not simultaneously been submitted to any other journal, nor is it under consideration for publication by any other journal. If any portion of the work submitted has appeared elsewhere, the quoted material is properly cited and credit is given to the original publisher. The submitting author (or the principal and corresponding author of the work) also assures the editors of IJVTPR that he or she has obtained all required written permissions from any quoted authors or publishers of quoted materials. The submitting author also agrees to hold IJVTPR and its editorial staff harmless from any infractions of copyright law that may be discovered at any time in the future in the submitted work. The author assures the editorial staff at IJVTPR that none of the work submitted is plagiarized, and that any recycled or precycled material by the author is identified as such with proper credits in the text to any other parties holding a copyright interest in the quoted material.